スポンサーリンク
近畿大学 産婦人科 | 論文
- Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma : Japan Clinical Oncology Group study (JCOG 9305)
- Randomized phase II study of concurrent and sequential combinations of rituximab plus CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) chemotherapy in untreated indolent B-cell non-Hodgkin lymphoma : 7-year follow-up results
- Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma
- Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy
- 2. Rapld Flow-Through Cytofluorometryによる婦人科癌の自動細胞診断に関する研究
- 19. 子宮頚扁平上皮癌の進展に伴なう細胞像の推移 : 特に浸潤の有無, 深達度と細胞像の関連 (第1群 悪性腫瘍 (1〜27))
- 梅毒妊婦より出生した児の管理
- 環境因子(感染)--性病 (産婦人科プライマリ・ケアの背景)
- 分娩の実際におけるPGE2経口剤のかかわりとその臨床的意義
- Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma
- Relevance of monitoring metabolic reduction in patients with relapsed or refractory follicular and mantle cell lymphoma receiving bendamustine : a multicenter study
- c-Maf suppresses human T-cell leukemia virus type 1 Tax by competing for CREB-binding protein
- 第18回日本臨床細胞学会秋期大会を終えて(総会まとめ, 第18回日本臨床細胞学会秋期大会抄録)
- Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab : A multicenter phase II study
- Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
- Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
- Heterogeneity in clonal nature in the smoldering subtype of adult T-cell leukemia : continuity from carrier status to smoldering ATL
- 上皮内癌および高度異形成上皮の臨床
- Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low-and low-intermediate risk, aggressive non-Hodgkin's lymphoma : final results of the Japan Clinical Oncology Group Study, JCOG95
スポンサーリンク